Research ArticleCancer

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3

See allHide authors and affiliations

Science Translational Medicine  17 Oct 2018:
Vol. 10, Issue 463, eaat5775
DOI: 10.1126/scitranslmed.aat5775

Log in to view full text

Log in through your institution

Log in through your institution

Navigate This Article